Glaxo’s Avandia Should Be Pulled, Doctors Say

U.S. Panel Vote on Avandia Recall Likely, FDA Says
A vote on whether to withdraw GlaxoSmithKline Plc’s diabetes pill Avandia from the market will likely come at a two-day meeting next month of outside advisers to the U.S. Food and Drug Administration, deputy commissioner Joshua Sharfstein said today in a telephone interview.

Read more on BusinessWeek

Glaxo’s Avandia Should Be Pulled, Doctors Say
GlaxoSmithKline Plc’s Avandia was linked to heart attacks and other cardiovascular complications in two new studies that the authors say should prompt U.S. regulators to pull the diabetes drug from the market.

Read more on BusinessWeek

Leave a Reply

Your email address will not be published. Required fields are marked *